🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My latest editorial on CAR-MSCs for the ISCT Telegraft - had a lot of fun writing this one! Check out the inspiration article from Saad kenderian linked within. Enjoy! #celltherapy

I am thrilled to have my video interview for the ISCT Telegraft Member Spotlight with Dr. Erja Kerkelä, Ph.D. out now! Enjoy this wonderful conversation with a fantastic researcher and champion of team science! youtu.be/k8XHLjlK_PY?si… via YouTube

📢 #mitochondria as a #therapeutic option this month in the latest issue of ISCT Telegraft by Drs. Caicedo lab from Universidad San Francisco de Quito 🔗 isctglobal.org/telegrafthub/b…

In this #UTM Telegraft article, Andrés Caicedo Lab & Sebastian Penaherrera C present #mitochondria as a cell-free therapeutic option. 🔗isctglobal.org/telegrafthub/b…

Telegraft Andrés Caicedo Lab Sebastian Penaherrera C ISCT 🤔What? 🧐#Mitochondria enabled #evolution& #diversification of complex life forms, driving energy production and support cellular #signaling, #survival& #cellularcommunication, leading to development of artificial mitochondrial transfer/transplant (AMT/T) pubmed.ncbi.nlm.nih.gov/37100996/

Telegraft Andrés Caicedo Lab Sebastian Penaherrera C ISCT 🤔Why?🧐The simplicity of AMT/T contrasts with complexity of studying its potential #therapeutic effect based on the principle that damaged cells and tissues require #mitochondria to support phenotypic recovery via nanotubular structures and microvesicles. pubmed.ncbi.nlm.nih.gov/33662580/

Telegraft Andrés Caicedo Lab Sebastian Penaherrera C ISCT 🤔Who?🧐There's no #commercial mitochondria preparations as #LivingDrug yet. However, the evidence that cells uptake #mitochondria from their surroundings or from other cells has spurred #interest in both in #academia and #industry. pubmed.ncbi.nlm.nih.gov/38013162/

Telegraft Andrés Caicedo Lab Sebastian Penaherrera C ISCT 🤔How?🧐#Challenges exist in the GMP #scaleup #manufacturing of mitochondria from healthy tissues in accordance to #pharmaceutical #regulations. Advances in production of other AdvancedTherapies might help in the sourcing of viable & functonal mitochondria pubmed.ncbi.nlm.nih.gov/32903493/

📢Now online! Human pluripotent stem cell-derived #retinal #pigment #epithelial cells #underthemicroscope by Dr. Laura Baqué Vidal Karolinska Institutet in the latest issue of Telegraft, the newsletter of the ISCT 🔗isctglobal.org/telegrafthub/b…

Advances in stem-cell #therapy could hold the key to treating age-related #macular degeneration (AMD), a leading cause of blindness. Learn how retinal pigment epithelial (RPE) cells are being developed to stop #vision loss & offer new hope for millions worldwide! #AMD Telegraft

Telegraft 🤔What?🧐RPE are specialized cells on the back of the eye playing a fundamental role in the homeostasis of the #retina, e.g. visual cycle recycling, phagocytosis of old photoreceptors, secretion of growth factors, transport of nutrients and water, capture of not-transduced light

Telegraft ISCT 🤔Why?🧐Age-related #macular #degeneration (AMD) is a prevalent progressive #blindness disease in the elderly worldwide caused by degeneration of #RPEs. Cell replacement therapies could help in the #treatment of AMD. 📚doi.org/10.22608/apo.2…

Telegraft ISCT 🤔Who?🧐Current strategies for treating AMD involve stem-cell-based RPE products develop in both academua and industry. 🔗doi.org/10.1080/078538…

Telegraft ISCT 🤔When?🧐The interest on transplanting #RPE into #AMD patients started in the early 90's, when #fetal tissue material was used to transplant young and healthy RPEs that were able to slightly rescue some visual acuity in patients. 🔗doi.org/10.1007/bf0018…

Telegraft ISCT 🤔Where?🧐Leading countries developing clinical development of stem-cell-based RPE products include USA, Japan, Israel, UK, China and Republic of Korea. In some other countries, developments are still on the preclinical stage, including Sweden, Spain, India, Finland, Singapore.

Telegraft ISCT 🤔How?🧐#Stem cell-based #RPE products are #ATMP produced in compliance with pharmaceutical #GMP standards. Current #protocols yield >98% pure RPEs, although some developers use cell sorting procedures to enrich #RPEs from other #impurities.

Telegraft ISCT 🤔Did you know that…🧐#RPE have granules of #melanin, the same substance found in the skin that protects us from #UVlight and responsible of the color of our #hair? This makes it easier to work with these cells because they can be easily spotted for their dark brown color.

Telegraft ISCT 💡If you want to learn more on #pluripotent #stem cell-derived #epithelial #retinal #pigmental #cells, please read Dr. Laura Baqué Vidal's article in the latest issue of @Telegraft following this link: isctglobal.org/telegrafthub/b…

📢now #online in the latest isse of ISCT Telegraft a recap of ICCBBA's a brief recap of #FORUM30 where I presented Current challenges in cell and gene therapy: a joint view from the European Committee of the ISCT and the The EBMT 🔗isctglobal.org/telegrafthub/b…

🌍 #FORUM30 united 102 experts from 36 countries to advance MPHO safety&traceability! Hosted by @ICCBBA, Centro Nazionale Trapianti, Centro Nazionale Sangue & supported by World Health Organization (WHO), we explored future therapies & global regulatory harmony. A pivotal step for patient care worldwide! 🔗iccbba.isbt128.org/forum30